Advanced Cancers

0

Pipeline Programs↗

26

Active Trials↗

40

Companies Involved↗

Advanced Cancers is an early-stage landscape with 0 programs across 40 companies. The most active players are Bristol-Myers Squibb, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

71/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Bristol-Myers Squibb

0 programs

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

0 programs

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

0 programs

Merck & Co.

0 programs

Eli Lilly

0 programs

Corvus Pharmaceuticals, Inc.

0 programs

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

100

clinical trials

Completed47 · 47%

Terminated14 · 14%

Recruiting12 · 12%

Active, not recruiting10 · 10%

Unknown status6 · 6%

Withdrawn5 · 5%

Other6 · 6%

Clinical Trials

Trial Activity

100 trials

TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers

Recruiting· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT05894421·92 enrolled

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Recruiting·TTizona Therapeutics, Inc·Phase 1·NCT04485013·240 enrolled

Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers

Recruiting·CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.·Phase 1·NCT06188624·150 enrolled

CT-95 in Advanced Cancers Associated With Mesothelin Expression

Recruiting·CContext Therapeutics Inc.·Phase 1·NCT06756035·70 enrolled

Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)

Recruiting·CCytoMed Therapeutics Pte Ltd·Phase 1·NCT05302037·12 enrolled

Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers

Recruiting·SShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.·Phase 1·NCT07260708·42 enrolled

GH55 for Advanced Cancers With MAPK Mutations: A Study on Safety and Early Results

Recruiting·SSuzhou Genhouse Bio Co., Ltd.·Phase 1/2·NCT06310382·110 enrolled

Clinical Trial of TQB3002 in Patients With Advanced Cancers

Recruiting· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT06662760·150 enrolled

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Recruiting·IImmunocore Ltd·Phase 1/2·NCT06840119·600 enrolled

A Study in Patients With Advanced Cancers

Recruiting·BBiOneCure Therapeutics Inc.·Phase 1/2·NCT05320588·332 enrolled

Plasmodium Immunotherapy for Advanced Cancers

Recruiting·CCAS Lamvac Biotech Co., Ltd.·Phase 1/2·NCT03375983·20 enrolled

Multilevel Veteran-centric Intervention to Improve Precision Oncology

Recruiting·VVA Office of Research and Development·Preclinical·NCT06825715·2,653 enrolled

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Active, not recruiting·CCheckpoint Therapeutics, Inc.·Phase 1·NCT03212404·272 enrolled

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

Active, not recruiting· Pfizer logo

Pfizer·Phase 1·NCT06870487·6 enrolled

Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers

Active, not recruiting·CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.·Phase 1·NCT05735496·219 enrolled

Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)